Novo Nordisk is “no longer the elephant in the room,” analysts led by Kerry Holford said as they upgraded the stock to Buy from Hold Tuesday. Following multiple guidance cuts this year, the market has reset expectations for the Danish pharma giant, allowing for a constructive debate on growth, catalysts, and valuation, Holford said.